BioSpace News Archive

Jeryl Hilleman, Chief Financial Officer of Intersect ENT, elected to board of directors

BioLife Solutions, Inc. announced that the Company’s second quarter 2018 financial results will be released before market open on Thursday, August 9, 2018, and that the Company will host a conference call and live webcast at 10:00 a.m. ET (7:00 a.m. PT) that morning. Management will provide an overview of the Company’s financial results and a general business update.

New Site Expands F1RST Up(r) Alliance, Increasing Volume of Patients Eligible for Clinical Trial Enrollment.

Sangamo Therapeutics, Inc. announced that the Company will release its second quarter 2018 financial results after the market closes on Wednesday, August 8, 2018.

Dr. Dillaha brings nearly 20 years of pharmaceutical industry experience to Nutriband.

Modeling and simulation’s positive impact on NDA and BLA approvals through July 1, 2018 has included first use, orphan and priority review drugs for multiple indications

BioTime to receive $21.6 million in cash and $21.6 million in a convertible/redeemable note for 14.4 million shares of AgeX Therapeutics

Pivot Pharmaceuticals Inc. is pleased to announce that it has entered into a Definitive Co-marketing and Distribution Agreement (“the Agreement”) with S.T.U. GmbH

Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has commenced a clinical trial to evaluate the Company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients.

Achieve Life Sciences, Inc. announced that it will report its second quarter 2018 financial results on Wednesday, August 8, 2018.